Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9595172 | 0.90 | PPM1D (0.35) | PPM1D | |
| SCHEMBL9595167 | 0.90 | PPM1D (0.35) | PPM1D | |
| SCHEMBL25752381 | 0.84 | PPM1D (0.32) | PPM1D | |
| SCHEMBL25118257 | 0.81 | TOP2A (0.33) | — | |
| SCHEMBL20780034 | 0.78 | — | — | |
| SCHEMBL14380455 | 0.77 | — | — | |
| SCHEMBL6933433 | 0.77 | — | — | |
| SCHEMBL26968744 | 0.77 | — | — | |
| SCHEMBL24512514 | 0.75 | — | — | |
| SCHEMBL12582851 | 0.75 | PRKAG1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230095696-A1 | OLIGOMERIC COMPOUNDS COMPRISING BACKBONE CONSTRAINED MACROCYCLES | IONIS PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| WO-2021234459-A9 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2022-02-03 | — | — | WO | disclosed |
| WO-2021234459-A2 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2021-11-25 | — | — | WO | disclosed |
| WO-2021146391-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C–P BONDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-22 | — | — | WO | disclosed |
| US-10865413-B2 | Oligomeric compounds comprising α-β-constrained nucleic acid | IONIS PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10221416-B2 | Oligomeric compounds comprising alpha-beta-constrained nucleic acid | IONIS PHARMACEUTICALS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170044539-A1 | OLIGOMERIC COMPOUNDS COMPRISING ALPHA-BETA-CONSTRAINED NUCLEIC ACID | IONIS PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230095696-A1 | OLIGOMERIC COMPOUNDS COMPRISING BACKBONE CONSTRAINED MACROCYCLES | NOP2, POLRMT, FBL | PPM1D 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.